Introduction
Living with non-cystic fibrosis bronchiectasis can create ongoing respiratory challenges that affect daily life, energy levels, and long-term lung health. The condition involves permanent airway damage that may lead to chronic cough, mucus buildup, recurrent lung infections, and worsening breathing symptoms over time. For many patients, disease management often requires ongoing monitoring, pulmonary care, and long-term treatment strategies.
Brinsupri is the first FDA-approved medication specifically indicated for non-cystic fibrosis bronchiectasis (NCFB). The medication was developed to target harmful inflammation in the lungs associated with the disease and represents a new treatment approach for patients living with bronchiectasis.
Brinsupri works differently from many traditional respiratory medications by targeting an enzyme called dipeptidyl peptidase 1 (DPP1). This enzyme plays a role in activating inflammatory proteins within neutrophils. Neutrophils are immune cells involved in chronic airway inflammation and lung damage.
By blocking DPP1 activity, Brinsupri may help reduce excessive inflammatory activity in the lungs and decrease pulmonary exacerbations associated with bronchiectasis. Clinical studies demonstrated reductions in bronchiectasis flare-ups in eligible patients receiving treatment.
The medication is administered orally once daily, which may be more convenient for some patients compared to more complex respiratory treatment regimens.
Although Brinsupri may provide an important new treatment option for bronchiectasis, specialty respiratory medications can also create affordability concerns. Patients may face high specialty pharmacy costs, insurance prior authorization requirements, ongoing pulmonary monitoring expenses, and medication-related out-of-pocket costs.
Those seeking affordable Brinsupri may benefit from Prescription Hope’s medication access services, which provide qualified individuals with advocacy and support during the patient assistance program application process.
Understanding how Brinsupri works, possible treatment benefits, side effects, and available medication access resources can help patients feel more informed when discussing bronchiectasis treatment options with their healthcare provider.
What Is the Brinsupri Patient Assistance Program?
The Brinsupri Patient Assistance Program provides qualified individuals access to affordable Brinsupri.
Pharmaceutical manufacturers understand the brand-name medications they bring to market may retail for more than many Americans can afford. To ease the financial burden and provide needed medication to more people, manufacturers often launch patient assistance programs to help patients save on their medication costs.
Unfortunately, some patients find these programs frustrating and complicated. However, there is a solution.
How Expert Advocates Help Make Medication More Affordable
Professional Application Management
Prescription Hope eases the stress of applying for a patient assistance program. Our team of advocates supports patients during the application process. Not only do we make sure all your forms are filled out correctly, but we also collect all needed documentation, gather signatures from healthcare providers, and submit your application on your behalf.
We continue to coordinate with the manufacturer throughout the processing stage, and then confirm shipping details after approval.
Brinsupri Price Comparison
vs
Estimated Retail Price*
30-Day Supply
Prescription Hope Price
Per Month, NO Matter The Retail Price
*Source: Drugs.com
Predictable Monthly Pricing
Our fee is simple. [Price-point] per month, per medication. No hassles or surprises.
For patients who do not qualify for their program, we’ll still help them find other ways to save. We’ve been able to successfully connect patients with substitute medications and their programs, discount cards, coupons, financial assistance, and more.
And if we can’t find a way for you to save on your medication? Then you pay nothing.
Ongoing Advocacy and Refill Support
Patients accepted into a patient assistance program, such as the Brinsupri cost assistance program, continue to benefit from Prescription Hope’s compassionate support. We manage refill schedules, document updates, yearly renewals, and more – all so you don’t have to.
Brinsupri Patient Assistance Eligibility
Wondering about Brinsupri eligibility? Need to know more about respiratory medication assistance eligibility?
Each program maintains specific patient assistance qualifications, though several categories are typically used:
Income: Each program sets its own requirements for the income threshold to qualify.
Insurance: Every program maintains an insurance coverage status requirement, though they vary.
Prescription: All programs require a valid prescription for the medication covered by the program.
U.S. Residency: All programs require patients to be legal U.S. residents to qualify.
Simple Enrollment With Expert Support
Starting Your Journey
If you’re looking for respiratory medication support and are looking to enroll in Brinsupri assistance, then follow these 6 steps:
- Submit Information: Complete our online enrollment form.
- Advocate Contact: After a completed form is received, a patient advocate will contact you within 1-2 business days.
- Document Collection: Once our team has prequalified you, we’ll collect all needed documentation.
- Provider Coordination: Our advocates will also work with your healthcare provider to collect all necessary signatures.
- Program Submission: We’ll gather everything together and submit your application packet to the manufacturer for processing. We continue to coordinate with the manufacturer throughout the processing stage.
- Medication Delivery: After approval, a patient can typically expect to receive their medication within 2 weeks. All medications are shipped directly to the patient’s doorstep or doctor’s office.
All medications are shipped directly from the manufacturer. Prescription Hope does not handle any medications.
Medication Delivery and Ongoing Support
After a patient has received specialty pharmacy assistance through a patient assistance program, Prescription Hope continues to work on their behalf.
We manage your account administration, handling refill schedules, document updates, yearly renewals, and more.
Understanding Brinsupri
How Brinsupri Works
Brinsupri works by blocking an enzyme called dipeptidyl peptidase 1 (DPP1).
DPP1 activates inflammatory proteins inside neutrophils, which are immune cells involved in chronic airway inflammation. In patients with bronchiectasis, excessive neutrophil-driven inflammation may contribute to airway damage, chronic symptoms, and recurrent pulmonary exacerbations.
By inhibiting DPP1 activity, Brinsupri helps reduce excessive inflammatory activity in the lungs that can contribute to disease progression and flare-ups associated with bronchiectasis.
The medication is classified as a first-in-class DPP1 inhibitor and represents a targeted treatment approach for non-cystic fibrosis bronchiectasis.
Brinsupri is administered orally as tablets and is typically taken once daily under the supervision of pulmonologists or respiratory disease specialists.
What Conditions Does Brinsupri Treat?
Brinsupri is FDA-approved for:
- Treatment of non-cystic fibrosis bronchiectasis (NCFB) in adults and pediatric patients 12 years of age and older
Bronchiectasis is a chronic lung disease involving permanent airway damage, mucus buildup, recurrent infections, and chronic airway inflammation.
Common symptoms of bronchiectasis may include:
- Chronic cough
- Excess mucus production
- Frequent respiratory infections
- Shortness of breath
- Fatigue
- Recurrent pulmonary exacerbations
Brinsupri became the first FDA-approved therapy specifically indicated for non-cystic fibrosis bronchiectasis.
Healthcare providers evaluate respiratory symptoms, pulmonary imaging, lung function, exacerbation history, and overall disease severity when determining whether Brinsupri may be an appropriate treatment option.
Benefits of Treatment
For some patients with bronchiectasis, Brinsupri may provide important disease-management benefits by targeting harmful airway inflammation associated with pulmonary exacerbations.
Potential benefits of Brinsupri treatment may include:
- Reduced bronchiectasis flare-ups (exacerbations)
- Reduced chronic airway inflammation associated with bronchiectasis
- Improvement in respiratory symptoms in some patients
- Once-daily oral administration
- First targeted therapy specifically approved for bronchiectasis
Clinical studies demonstrated reductions in pulmonary exacerbation frequency in eligible patients receiving Brinsupri treatment.
Because bronchiectasis is a chronic respiratory disease, ongoing pulmonary monitoring and individualized treatment management remain important throughout therapy.
Important Safety Information and Side Effects
Like all specialty respiratory medications, Brinsupri may cause side effects and carries important safety considerations. Patients should discuss the risks and benefits of treatment with their healthcare provider before starting therapy.
One important safety concern involves dental and oral adverse reactions. Gingival inflammation, tooth-related disorders, mouth irritation, and other dental complications have been reported during treatment.
Patients may require regular dental evaluations throughout therapy.
Common side effects associated with Brinsupri may include:
- Skin rash
- Dry skin
- Gum or dental problems
- Tooth pain
- Mouth irritation
- Respiratory symptoms
- Mild gastrointestinal symptoms
Additional important safety considerations may include:
- Skin reactions and rash
- Laboratory abnormalities requiring monitoring
- Potential liver-related concerns requiring routine testing
- Fetal harm during pregnancy
Patients should promptly report:
- Signs of infection
- Worsening respiratory symptoms
- Unusual inflammatory reactions
- Significant dental or oral symptoms
Patients should inform their healthcare provider about:
- Vaccination history
- Dental issues
- All medications and supplements
- Pregnancy status or plans
Blood tests and routine follow-up monitoring may be recommended during treatment, including liver function testing and pulmonary assessments.
Patients should also discuss vaccination plans with their healthcare provider before and during therapy.
Brinsupri does not currently carry an FDA boxed warning.
Access to Multiple Medications
Those looking for chronic lung disease treatment support may also need multiple medication assistance.
Prescription Hope can help.
Whether a patient qualifies for one or many brand-name medications on our list of available medications, we may be able to help. Our service fee of $70.00 per month, per medication, remains the same no matter how many medications an individual qualifies for.
Why Choose Prescription Hope for Brinsupri Assistance
Experienced Advocacy Support
In 2006, Prescription Hope was founded with the mission to help patients across America save on their medication costs. Today, Prescription Hope has helped over 100,000 people save a combined hundreds of millions of dollars.
Our Florida-based team of expert advocates is eager to help you find ways to save on your monthly medication costs.
Ongoing Medication Management
But our service doesn’t stop once you are accepted into a patient assistance program. We continue to handle refill schedules, document updates, yearly renewals, and more.
Transparent Monthly Pricing
Our service rate of $70.00 per month, per medication is simple and clear. You won’t find upcharges, hidden fees, or variable pricing. What you see is what you get.
Nationwide Medication Access Support
Our network has extended to hundreds of manufacturers and tens of thousands of healthcare providers. We leverage our extensive network to help patients save on their medication and get access to savings options, such as specialty respiratory medication assistance.
If you want to apply for the Brinsupri Patient Assistance Program, then enroll with Prescription Hope today!
